Multiple myeloid programs

Status: drug discovery

Compugen’s early stage programs are focused largely on myeloid targets addressing a range of mechanisms of action. Myeloid biology is a critical component of immune suppression. The myeloid lineage of the immune system includes suppressive macrophages, immune cells that are highly immune suppressive in the tumor microenvironment, and that can affect the anti-tumor immune response via multiple mechanisms of action. As such, blocking myeloid targets may offer a complementary strategy to immune checkpoint inhibition, providing new treatment solutions for non-responsive or relapsing patients and expanding the patient population responsive to immunotherapies. The Company’s discovery platform has been enhanced to identify new myeloid targets within the tumor microenvironment. Myeloid CGEN-target candidates have been identified within the tumor microenvironment of multiple cancers and are pursued by the Company.


Max 1mb, accepted formats: pdf, doc, docx, rtf
[recaptcha size:compact]
Message Sent. Thank You!